Assessment of the Production of Value-Added Chemical Compounds from Sewage Sludge Pyrolysis Liquids

A procedure to analyze sewage sludge (SS) pyrolysis liquids based on solvent fractionation has been developed. Pyrolysis liquids are separated into three different fractions: heptane soluble (Hep-sol), dichloromethane soluble (DCM-sol), and hydrochloric acid soluble (HCl-sol). Diverse techniques (GC-MS, UPLC-TOF-MS) were employed to qualitatively and quantitatively analyze liquid fractions to assess the potential production of value-added chemicals. Aliphatic hydrocarbons, aliphatic nitriles, and steroids were mostly separated in the Hep-sol fraction, phenols and fatty acids in the DCM-sol fraction, and carboxylic acids and amides in the HCl-sol fraction. The largest production was obtained for ammonia (10–14 kg per tonne of SS) and a-olefins (8–9 kg per tonne of SS). The potential production of some of these value-added chemicals from SS pyrolysis liquid was compared with their current European production. In the case of a-olefins, 16 % of their European production could be achieved by SS pyrolysis

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease : TRENDY Study of ENEIDA

Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment